Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Jan;29(1):148-55.
doi: 10.1111/jdv.12490. Epub 2014 Mar 25.

Alleviation of Chronic Venous Leg Ulcers With a Hand-Held Dielectric Barrier Discharge Plasma Generator (PlasmaDerm(®) VU-2010): Results of a Monocentric, Two-Armed, Open, Prospective, Randomized and Controlled Trial (NCT01415622)

Affiliations
Randomized Controlled Trial

Alleviation of Chronic Venous Leg Ulcers With a Hand-Held Dielectric Barrier Discharge Plasma Generator (PlasmaDerm(®) VU-2010): Results of a Monocentric, Two-Armed, Open, Prospective, Randomized and Controlled Trial (NCT01415622)

F Brehmer et al. J Eur Acad Dermatol Venereol. .

Abstract

Background: Cold atmospheric plasma (CAP, i.e. ionized air) is an innovating promising tool in reducing bacteria.

Objective: We conducted the first clinical trial with the novel PlasmaDerm® VU-2010 device to assess safety and, as secondary endpoints, efficacy and applicability of 45 s/cm(2) cold atmospheric plasma as add-on therapy against chronic venous leg ulcers.

Methods: From April 2011 to April 2012, 14 patients were randomized to receive standardized modern wound care (n = 7) or plasma in addition to standard care (n = 7) 3× per week for 8 weeks. The ulcer size was determined weekly (Visitrak® , photodocumentation). Bacterial load (bacterial swabs, contact agar plates) and pain during and between treatments (visual analogue scales) were assessed. Patients and doctors rated the applicability of plasma (questionnaires).

Results: The plasma treatment was safe with 2 SAEs and 77 AEs approximately equally distributed among both groups (P = 0.77 and P = 1.0, Fisher's exact test). Two AEs probably related to plasma. Plasma treatment resulted in a significant reduction in lesional bacterial load (P = 0.04, Wilcoxon signed-rank test). A more than 50% ulcer size reduction was noted in 5/7 and 4/7 patients in the standard and plasma groups, respectively, and a greater size reduction occurred in the plasma group (plasma -5.3 cm(2) , standard: -3.4 cm(2) ) (non-significant, P = 0.42, log-rank test). The only ulcer that closed after 7 weeks received plasma. Patients in the plasma group quoted less pain compared to the control group. The plasma applicability was not rated inferior to standard wound care (P = 0.94, Wilcoxon-Mann-Whitney test). Physicians would recommend (P = 0.06, Wilcoxon-Mann-Whitney test) or repeat (P = 0.08, Wilcoxon-Mann-Whitney test) plasma treatment by trend.

Conclusion: Cold atmospheric plasma displays favourable antibacterial effects. We demonstrated that plasma treatment with the PlasmaDerm® VU-2010 device is safe and effective in patients with chronic venous leg ulcers. Thus, larger controlled trials and the development of devices with larger application surfaces are warranted.

Trial registration: ClinicalTrials.gov NCT01415622.

Similar articles

See all similar articles

Cited by 28 articles

See all "Cited by" articles

Publication types

Associated data

LinkOut - more resources

Feedback